<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Bupropion for the treatment of apathy in Huntington&apos;s disease: A multicenter, randomised, double-blind, placebocontrolled, prospective crossover trial</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2017-03-21">March 21, 2017</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Harald</forename><surname>Gelderblom</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neuropsychiatry</orgName>
								<orgName type="institution">Charite ´-Universita ¨tsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Torsten</forename><surname>Wu ¨stenberg</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">Charite ´-Universita ¨tsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tim</forename><surname>Mclean</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">European Huntington&apos;s Disease Network</orgName>
								<address>
									<settlement>Ulm, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lisanne</forename><surname>Mu ¨tze</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">European Huntington&apos;s Disease Network</orgName>
								<address>
									<settlement>Ulm, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wilhelm</forename><surname>Fischer</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Ulm</orgName>
								<address>
									<settlement>Ulm, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Carsten</forename><surname>Saft</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution" key="instit1">Huntington-Center NRW</orgName>
								<orgName type="institution" key="instit2">St. Josef Hospital</orgName>
								<orgName type="institution" key="instit3">Ruhr-University</orgName>
								<address>
									<settlement>Bochum, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rainer</forename><surname>Hoffmann</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution" key="instit1">Huntington-Center NRW</orgName>
								<orgName type="institution" key="instit2">St. Josef Hospital</orgName>
								<orgName type="institution" key="instit3">Ruhr-University</orgName>
								<address>
									<settlement>Bochum, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sigurd</forename><surname>Su ¨ssmuth</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">European Huntington&apos;s Disease Network</orgName>
								<address>
									<settlement>Ulm, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><surname>Schlattmann</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Institute of Medical Statistics</orgName>
								<orgName type="department" key="dep2">Computer Sciences and Documentation</orgName>
								<orgName type="institution">Jena Universityhospital</orgName>
								<address>
									<settlement>Jena, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Erik</forename><surname>Van Duijn</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">Leiden University Medical Centre</orgName>
								<address>
									<addrLine>The Netherlands</addrLine>
									<settlement>Leiden</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bernhard</forename><surname>Landwehrmeyer</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">European Huntington&apos;s Disease Network</orgName>
								<address>
									<settlement>Ulm, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Ulm</orgName>
								<address>
									<settlement>Ulm, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Josef</forename><surname>Priller</surname></persName>
							<email>josef.priller@charite.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Neuropsychiatry</orgName>
								<orgName type="institution">Charite ´-Universita ¨tsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department" key="dep1">Cluster of Excellence NeuroCure</orgName>
								<orgName type="department" key="dep2">DZNE and BIH</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff8">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">National Association of Statutory Health Insurance Funds</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff9">
								<orgName type="institution">University of Toronto</orgName>
								<address>
									<country key="CA">CANADA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff10">
								<address>
									<settlement>Rochester</settlement>
									<region>New York</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Bupropion for the treatment of apathy in Huntington&apos;s disease: A multicenter, randomised, double-blind, placebocontrolled, prospective crossover trial</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-03-21">March 21, 2017</date>
						</imprint>
					</monogr>
					<idno type="MD5">CA7499355066441D0F86242DCF94F61C</idno>
					<idno type="DOI">10.1371/journal.pone.0173872</idno>
					<note type="submission">Received: July 21, 2016 Accepted: February 28, 2017</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:15+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>JP HG EvD</term>
					<term>Data curation: LM TM PS TW</term>
					<term>Funding acquisition: JP BL</term>
					<term>Investigation: HG JP RH CS SS</term>
					<term>Methodology: HG JP TW WF PS LM BL</term>
					<term>Supervision: JP PS TW</term>
					<term>Visualization: HG</term>
					<term>Writing -original draft: HG</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>To evaluate the efficacy and safety of bupropion in the treatment of apathy in Huntington's disease (HD).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p><s>In this phase 2b multicentre, double-blind, placebo-controlled crossover trial, individuals with HD and clinical signs of apathy according to the Structured Clinical Interview for Apathy-Dementia (SCIA-D), but not depression (n = 40) were randomized to receive either bupropion 150/300mg or placebo daily for 10 weeks.</s><s>The primary outcome parameter was a significant change of the Apathy Evaluation Scale (AES) score after ten weeks of treatment as judged by an informant (AES-I) living in close proximity with the study participant.</s><s>The secondary outcome parameters included changes of 1. AES scores determined by the patient (AES-S) or the clinical investigator (AES-C), 2. psychiatric symptoms (NPI, HADS-SIS, UHDRS-Behavior), 3. cognitive performance (SDMT, Stroop, VFT, MMSE), 4. motor symptoms (UHDRS-Motor), 5. activities of daily function (TFC, UHDRS-Function), and 6. caregiver distress (NPI-D).</s><s>In addition, we investigated the effect of bupropion on brain structure as well as brain responses and functional connectivity during reward processing in a gambling task using magnetic resonance imaging (MRI).</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Apathy is a common behavioral syndrome in neuropsychiatric disorders with prefrontal cortex (PFC) and basal ganglia (BG) pathology, such as Huntington's disease (HD) <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>.</s><s>It is broadly defined as the primary absence of motivation, lack of initiative and drive, as well as emotional indifference <ref type="bibr" target="#b2">[3]</ref>.</s><s>Apathy can be divided into three major syndrome domains-deficient emotional-affective function, cognitive function, or auto-activation <ref type="bibr" target="#b1">[2]</ref>.</s></p><p><s>In HD, apathy is the most common neuropsychiatric syndrome that correlates directly with disease progression <ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref>.</s><s>Loss of dopamine (DA) receptor expression in fronto-striatal circuits was proposed as a key pathophysiological mechanism of apathy in HD <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b7">8]</ref>.</s><s>Neurodegeneration begins in the striatum as early as 15 years prior to motor onset, and then extends to frontal and PFC cortex regions <ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref>.</s><s>Pathological changes in the orbital and medial PFC and the projections to limbic brain regions, predominantly the ventral striatum (VS), have been associated with the development of apathy in HD <ref type="bibr" target="#b1">[2]</ref>.</s><s>Magnetic resonance imaging (MRI) is capable of measuring atrophy <ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref> as well as alterations in mesolimbic DA processes <ref type="bibr" target="#b14">[15,</ref><ref type="bibr" target="#b15">16]</ref>, which are linked to anticipation and processing of reward or punishment.</s><s>In premanifest HD patients, an aberrant ventral striatal response during a monetary incentive delay task has been observed <ref type="bibr" target="#b16">[17]</ref>.</s></p><p><s>Despite of the high prevalence and disease burden of apathy in HD, research on therapeutic options for apathy is rare, and no effective treatment is at hand <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b18">19]</ref>.</s><s>This is the first controlled trial (CT) on the treatment of apathy in HD.</s><s>It was the aim of this trial to evaluate the efficacy and safety of bupropion in the treatment of apathy in HD.</s><s>We chose the antidepressant bupropion for its mode of action of blocking norepinephrine and DA reuptake, thereby potentially increasing DA neurotransmission in areas relevant for apathy.</s><s>In addition, several single case reports and results of small series suggested the effectiveness of bupropion for the treatment of apathy in HD and other neurodegenerative diseases <ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref>.</s><s>In addition, we investigated the effect of bupropion on DA-associated reward processing in an established gambling task using fMRI <ref type="bibr" target="#b22">[23,</ref><ref type="bibr" target="#b23">24]</ref>.</s></p><p><s>(www.huntingtonstudygroup.org);</s><s>Huntington Society of Canada (HSC), Ontario, Canada (www.</s><s>huntingtonsociety.ca);</s><s>European Huntington's Disease Network (EHDN), Ulm, Germany (www.</s><s>euro-hd.net);</s><s>Cluster of Excellence NeuroCure, Charite ´-Universita ¨tsmedizin Berlin (www.</s><s>neurocure.de).</s><s>EHDN funded data collection but had no role in study design, data analysis, decision to publish, or preparation of the manuscript.</s><s>HSG, HSC and NeuroCure had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</s></p><p><s>Competing interests: Harald Gelderblom has no competing interests.</s><s>Torsten Wu ¨stenberg has no competing interests.</s><s>Tim McLean has no competing interests.</s><s>Lisanne Mu ¨tze has no competing interests.</s><s>Wilhelm Fischer has no competing interests.</s><s>Carsten Saft has no competing interests in relation to the submitted trial.</s><s>Carsten Saft reports grants from Teva Endowed Professorship, grants from 'Cure Huntington's Disease Initiative´(CHDI), grants from Biogen, personal fees from Temmler Pharma GmbH &amp; Co.KG, personal fees from Desitin, received institutional compensation and/or travel or accommodation payments in the context of the observational studies Registry-Study of the Euro-HD-Network, the ENROLL-HD Study (CHDI), in the context of the MitoNet-study, and in the context of the ACR16-Study (Neurosearch), the AFQ-Study (Novartis), the Selisistat-Studies (Siena Biotech), the PRIDE-HD-Study (TEVA), the Amaryllis-Study (Pfizer) as well as the IONIS Antisense trial (IONIS-HTTRx).</s><s>He is a member of the EHDN (European Huntington's Disease Network) "Registry Steering Committee" since 01/2013, since 04/13 a member of the "Stiftungsrates der Huntington-Stiftung" (Research foundation), since 06/13 on steering committee: Deep Brain Stimulation (DBS) of the Globus pallidus (GP) in Huntington's disease: A prospective, randomizied, controlled multi-centre study, since 09/14 a member of the EHDN "Scientific and Bioethics Advisory Committee (SBAC)", and a member of the Scientific Committee of the German patient organisation (Deutsche Huntington Hilfe).</s><s>Rainer Hoffmann has no competing interests.</s><s>Sigurd Su ¨ssmuth has no competing interests.</s><s>Peter Schlattmann has no competing interests.</s><s>Erik van Duijn has no competing interests.</s><s>Bernhard Landwehrmeyer has no competing interests in relation to the submitted trial.</s><s>He has provided consulting services, advisory board functions, clinical trial services and/or lectures for Affiris, AOP Orphan Pharmaceuticals AG, Desitin, GlaxoSmithKline, Hoffmann-La Roche, Ionis Pharma, Pfizer, Prana Biotechnology, Raptor Pharmaceuticals, and TEVA and has received ACTION-HD (Apathy cure through Bupropion in Huntington's disease) is a multi-center, randomized, double-blind, placebo-controlled, 2x2 crossover phase 2b investigator-initiated trial (IIT) that was conducted at four sites in Germany between May 2012 (recruitment of first patient) and May 2014 (last patient leaving the trial).</s><s>The ACTION-HD trial was registered at the EudraCT clinical trial register (EudraCT number 2009-013698-16) on 24 th March 2011 prior to inclusion of the first patient.</s><s>We later registered the trial at clinicaltrials.gov.</s><s>The authors confirm that all ongoing and related trials for this drug/intervention are registered.</s><s>The protocol for this trial is available as supporting information; see S1 Clinical trial protocol.</s><s><ref type="bibr">[17.11.2011]</ref>).</s><s>The study was conducted in accordance with the ethical principles laid out in the Declaration of Helsinki (1996) and consistent with Good Clinical Practice.</s><s>All study participants provided informed consent before any study-related procedures were undertaken.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethics statement</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study participants</head><p><s>After signing the informed consent form, genetically verified HD patients aged 25 to 75 years and informants were included in the trial.</s><s>Apathy was ascertained by the Structured Clinical Interview for Apathy-Dementia (SCIA-D).</s><s>A caregiver living in close proximity to the patient had to participate as informant.</s><s>Patients with clinically significant depression (NPI depression score &gt;4), schizophreniform psychosis, a Mini-Mental State Examination (MMSE) &lt; 18, marked chorea bucco-oro-lingual, of face, trunk or extremities, active suicidality based on the answer "yes" to questions 4 and 5 of the "suicidal ideation" section of the Columbia-Suicide Severity Rating Scale (C-SSRS), or treatment with antipsychotics other than tiapride, MAO-B inhibitors, amantadine, levodopa, D-or D,L-amphetamine or psychostimulants within 1 month prior to the first dose were excluded.</s><s>A full list of inclusion and exclusion criteria is provided in S1 Clinical trial protocol in the supporting information.</s><s>The allocation to either of two treatment arms was based on a central randomization code generated by means of the randomization procedure of nQuery 7.0.</s><s>and performed by the study biometrician (PS).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Primary and secondary objectives and sample size justification</head><p><s>The primary objective was to determine the influence of bupropion compared to placebo on the change of apathy as quantified by the informant-based Apathy Evaluation Scale (AES)-I, where I [informant] is a family member or friend familiar with the daily activities of the subject (score: 18-72 points; adjusted for the baseline values at week 0 or 13, respectively).</s><s>Due to lack of published data, the power calculation was based on an unpublished patient cohort (n = 50) followed at the Centre for Brain Repair, University of Cambridge, UK (data generously provided by Sarah L. Mason and Roger A. Barker) for three years, where the AES-I showed a mean score of 31 points (standard deviation SD = 15.6).</s><s>We defined clinically significant improvement as a 35% reduction of the mean AES-I score and calculated an absolute effect size of 0.35 Ã 31 points = 10.85 points.</s><s>An estimate of 10 points was used for sample size determination and a within subjects SD of 15.0 was assumed.</s><s>Accordingly, with a sample size in each group of 19 and a 2x2 crossover design, we would have 80% power to detect a difference in means of 10.00 (the difference between a Treatment 1 mean, μ1, of 31 and a Treatment 2 mean, μ2, of 21) assuming that the crossover ANOVA p MSE is 15.00 (the standard deviation of differences is 21.21) using a two group t-test (Crossover ANOVA) with a 0.05 two-sided significance level.</s><s>In order to account for potential dropouts, we decided to randomize 40 patients.</s><s>Sample size calculation was performed with nQuery 7.0.</s></p><p><s>The secondary objectives included an assessment of: 1. the safety and tolerability of bupropion in HD, 2.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dosing and study plan</head><p><s>Study participants and informants took part in 8 study visits S1 Fig. Prior to and after crossover (week 11), all study participants received once daily 150 mg bupropion or placebo for 2 weeks, followed by 300 mg bupropion or placebo per day for 8 weeks.</s><s>In the case of intolerable side effects after the dose increase to 300 mg bupropion or placebo, dosing was reduced to 150 mg and maintained for the duration of the treatment arm.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Assessments</head><p><s>Assessment sequence: Apathetic HD patients are likely to have progressed disease <ref type="bibr" target="#b4">[5]</ref>, restricted cognitive resources, a short attention span and may experience fatigue during studyrelated procedures.</s><s>We therefore designed a hierarchy of assessments that took these potential limitations into account.</s></p><p><s>Assessment of demographic characteristics including medical history, concurrent medication and physical examination was performed in a structured fashion based on the EHDN platform, which was approved by the institutional review boards of the participant centers for the observational REGISTRY study of the EHDN.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Structured Clinical Interview for Apathy-Dementia (SCIA-D).</head><p><s>To diagnose apathy and rate the severity of apathy, the SCIA-D was performed at screening, prior to and after each treatment interval.</s><s>The SCIA-D was originally validated in patients with AD.</s><s>It assesses seven domains relative to the individual's previous level of functioning and incorporates the judgment of the informant <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b24">25]</ref>.</s><s>A German version (Translation: S. Forstmeier, M. Mortby, 2008) authorized by S.E.</s><s>Starkstein (University of Western Australia, Australia) was used.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Apathy Evaluation Scale (AES).</head><p><s>To rate symptoms of apathy, the AES was filled in by the informant (AES-I; primary outcome variable), the study participant (AES-S), and the clinical investigator (AES-C) after a semi-structured clinical interview of participant and informant by the clinical investigator at the beginning of each study visit.</s><s>Participant and informant had to perform the AES separately.</s><s>Both were instructed not to discuss the answers.</s><s>The AES scale consists of 18 items, each of which is assessed on a four-point Likert scale, so that the total score ranges from 0 to 54 <ref type="bibr" target="#b25">[26,</ref><ref type="bibr" target="#b26">27]</ref>.</s><s>The AES was not used as an inclusion criterion, as there is no validated cut-off for the presence of clinically relevant apathy in HD.</s><s>To ensure uniformity of SCIA-D and AES procedures, we produced a teaching video.</s><s>In addition, study personnel were trained in published guidelines for performance <ref type="bibr" target="#b26">[27]</ref>.</s><s>To minimize inter-rater variability, virtually every study participant was rated by the same clinical investigator with longstanding experience in HD during the entire course of the study.</s></p><p><s>Neuropsychiatric Inventory (NPI).</s><s>To exclude comorbid depression, a "depression/ dysphoria" score of 4 on the NPI was required for study inclusion (maximum score is 12 [frequency x severity]).</s><s>To evaluate effects and side effects of the study medication, the domains "depression/dysphoria", "apathy/indifference" and "irritability/lability" were assessed prior to and after each treatment episode.</s><s>In addition, caregiver distress (NPI-D) was assessed from 0 (not at all) to 5 (extremely).</s></p><p><s>The Hospital Anxiety and Depression Scale combined with the Snaith Irritability Scale (HADS-SIS).</s><s>To test for symptoms of depression and signs of irritability, the HADS-SIS was performed prior to and after each treatment episode.</s><s>The HADS is a self-report questionnaire that consists of 14 items rating symptoms of depression (7 items) and anxiety (7 items).</s><s>The SIS rates inward and outward irritability (8 items).</s><s>Each item is rated on a four-point scale.</s></p><p><s>Unified Huntington's Disease Rating Scale (UHDRS)-99.</s><s>The UHDRS-99 was performed prior to and after each treatment episode.</s><s>The UHDRS-99 is an extension and update of the UHDRS, the most commonly used and validated clinical rating scale to assess motor (including chorea and dystonia), psychiatric, and cognitive (Stroop, Verbal Fluency Test, Symbol Digit Modalities Test) symptoms of HD, and to determine functional capacity <ref type="bibr" target="#b27">[28]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Columbia-Suicide Severity Rating Scale (C-SSRS).</head><p><s>To exclude suicidal ideation or behavior, this semi-structured scale was performed during every study visit and telephone interview.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mini Mental Status Examination (MMSE).</head><p><s>To assess the cognitive state of the study participant, the MMSE was administered prior to and after every treatment episode.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Structural and functional magnetic resonance imaging</head><p><s>Gambling task.</s><s>To assess brain responses and functional connectivity during reward processing by fMRI, an established gambling task known to elicit strong dopaminergic responses in the VS was used <ref type="bibr" target="#b23">[24,</ref><ref type="bibr" target="#b28">29]</ref>.</s><s>A detailed description of MRI parameters, determination of regions of interest (ROI), gambling task paradigm and the applied image-processing pipeline is provided in the S1 Supplemental methods and S2-S4 Figs.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data collection and statistical analysis</head><p><s>Data collected on each patient were recorded on an electronic case report form (eCRF) based on the EHDN REGISTRY platform.</s><s>During the study, a 100% monitoring was performed in all centres and eCRF data entries were checked using computerized and manual means to identify problem fields.</s><s>All study-related documentation including the study master file was collected in an ACTION-HD study section of the EHDN web portal accessible to all study personnel.</s><s>During the entire study, weekly telephone conferences were held by the study coordination team.</s></p><p><s>Statistical analysis.</s><s>For efficacy analysis, the confirmatory inferential statistical evaluation of the primary target parameter was based on a linear mixed effects model with the AES-I score as dependent variable.</s><s>The model used treatment group and period as fixed factors, and the baseline AES-I score as covariate.</s><s>Random effects were introduced for the intercepts, thus taking the correlation within participants into account.</s><s>All secondary efficacy variables were primarily evaluated by using descriptive statistics.</s><s>If applicable, a similar analysis was performed for secondary variables in an explanatory manner.</s><s>A detailed description of image analysis procedures is provided in the S1 Supplemental methods.</s><s>An excerpt of the data that will allow full analysis of all results shown in the manuscript except for patient-relevant data that are protected by confidentiality regulations are available to all interested researchers by contacting the EHDN Scientific and Bioethics Advisory Committee (SBAC) at actionhd_datarequest@euro-hd.net.</s></p><p><s>Safety analysis.</s><s>The safety analysis was performed as outlined in the study protocol (S1 Clinical trial protocol, page 23-30).</s><s>After the last patient left the study and prior to the database closure, protocol deviations were assessed by the site investigators during a blind data review meeting in April 2014 and classified as "minor" or "major" based on joint decisions.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>Between May 2012 and October 2013, 40 apathetic HD patients were randomized into two treatment groups (20/20) Fig 1 <ref type="figure">.</ref></s><s>The subject characteristics are summarized in Table <ref type="table" target="#tab_2">1</ref>.</s><s>Eighteen study participants consented to participate in the adjunct MRI study.</s><s>The last study participant finished the study in April 2014.</s><s>The study database was locked on May 30, 2014.</s><s>Other than duration of disease (group 1: 8.4 ± 3.6 years vs. group 2: 5.5 ± 2.4 years; p&lt;0.05), there were no statistically significant treatment group differences for any demographic parameter or baseline values of primary or secondary outcome variables Table <ref type="table" target="#tab_2">1</ref>.</s></p><p><s>A first important observation of the study was that the study participants rated their symptoms of apathy (AES-S) as significantly less severe than the caregivers (AES-I; t (df = 38) = -6.0504,</s><s>p&lt;0.001) or the clinical investigators (AES-C; t (df = 38) = -5.6101,</s><s>p&lt;0.001)</s><s>Table <ref type="table" target="#tab_2">1</ref>.</s></p><p><s>Due to major protocol violations, two study participants had to be excluded from the per protocol analysis, because one did not follow the washout and crossover medication sequence between visit 4 and visit 4a, and the other took less than 80% of the study medication during the treatment period.</s><s>Four participants discontinued the study; two for unwillingness to resume study visits, and one because of increased irritability while on bupropion.</s><s>A fourth participant discontinued the study due to mood changes (cf.</s><s>severe adverse events (SAEs), participant five).</s></p><p><s>As for the safety and tolerability of bupropion, 21 of 40 study participants had at least one of 56 AEs.</s><s>Five AEs were rated as severe and 11 AEs were rated as moderate.</s><s>The five SAEs resulted in hospitalizations: two after a fall, in one case with a shoulder fracture and an ensuing depression, a third for an elective varicose vein stripping, all on placebo.</s><s>The fourth participant with a SAE was hospitalized after a short episode of lack of responsiveness three days after the ending of bupropion treatment (visit 4; S1 Fig) <ref type="figure">.</ref></s><s>A fifth participant was hospitalized due to an increased instability of mood, irritability and aggression which evolved one day prior to the tapering of bupropion and while on concomitant medication with venlafaxine.</s><s>The 11 moderate AEs included a mild to moderate increase in chorea and gait disorder (7 on bupropion/4 on placebo), an increase in irritability (1 on bupropion/6 on placebo), concentration difficulties (3 on placebo), a sleeping disorder (2 on bupropion), agitation and restlessness (1 on bupropion/1 on placebo), and an increase of perseverative thinking (1 on placebo).</s><s>One study participant developed disinhibition, another hyperphagia with an increase of 20 kg of body weight while on bupropion.</s><s>No participant developed active suicidality (answer "yes" to questions 4 and 5 of the "suicidal ideation" section of the C-SSRS), or indicated suicidal ideation upon questioning by the clinical investigators.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Bupropion does not change apathy in HD as quantified by the AES-I</head><p><s>Comparing the primary outcome variable between the treatment groups using the linear mixed model adjusting for baseline, there was a slight but statistically non-significant change of the AES-I score due to bupropion treatment, which amounted to -0.81 (95% CI = -3.12,</s><s>1.52) in the full analysis set, and to -0.09 (95% CI = -2.56,</s><s>2.39) in the per protocol set Table <ref type="table" target="#tab_3">2</ref>.</s></p><p><s>In any case, this level of change had no clinical relevance (defined as a change of 10 points or more on the AES, cf.</s><s>Materials &amp; methods).</s><s>The results did not change when using multiple imputations to take missing values into account.</s><s>Including random effects for the site produced a corresponding variance of random effects equal to zero, showing that there was no relevant heterogeneity between sites.</s><s>When we grouped the AES questions according to the three major apathy syndrome domains (cognitive, behavioral, emotional) and analyzed them separately, we still failed to observe a significant treatment effect on any of the three apathy domains.</s><s>However, when looking at each AES question separately, a significant treatment effect was observed for question 2 "he/she get things done during the day" (-0.22 [95% CI = -0.44,</s><s>0.01; p&lt;0.05]).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Bupropion does not change apathy in HD as quantified by the AES-S, AES-C, NPI-Apathy or UHDRS-Apathy</head><p><s>For the secondary outcome parameters used to quantify apathy in this study, we observed a slight treatment effect of bupropion measured by the AES-C (-1.26 [95% CI = -3.7,</s><s>1.2]), the NPI-Apathy (-0.53 [95% CI = -1.6,</s><s>0.5]) and the UHDRS-Apathy (-0.71 [95% CI = -2, 0.6]), none of which were statistically significant or clinically relevant Table <ref type="table" target="#tab_3">2</ref>.</s><s>The study participants  Patients were allocated to group1 (1st treatment episode: bupropion, followed by washout and crossover, followed by 2nd treatment episode: placebo) or group 2 (1st treatment episode: placebo, followed by washout and crossover, followed by 2nd treatment episode: bupropion).</s><s>c Values are given as mean ± SD (standard deviation) themselves rated a reduction of apathy in the AES-S (-2.23 [95% CI = -4.9,</s><s>0.4]), which was not significant or clinically relevant Table <ref type="table" target="#tab_3">2</ref>.</s><s>When we grouped the AES-C and AES-S questions according to the three major apathy syndrome domains, we again did not observe a significant treatment effect on any of the three apathy domains.</s><s>Looking at the questions separately, a significant bupropion treatment effect was revealed for question 17 "he/she has initiative" of the AES-C (-0.25 [95% CI = -0.5, 0; p&lt;0.05]).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Bupropion does not influence motor performance, irritability, cognition, or function in HD</head><p><s>No significant changes in irritability (HADS-SIS, NPI-Irritability) or motor function (UHDRS-motor) due to treatment with bupropion were observed Table <ref type="table" target="#tab_3">2</ref>.</s><s>This was somewhat surprising as some clinical investigators noted an increase in irritability and chorea in some study participants during the trial, as has been described in a case series.</s><s>However, this could not be attributed to bupropion after unblinding of the trial.</s><s>Cognition, in particular executive function, did not improve under medication with bupropion.</s><s>Moreover, the UHDRS-Function assessment tool and the UHDRS-Independence scale did not reveal any significant changes in the activities of daily living as a result of bupropion treatment Table <ref type="table" target="#tab_3">2</ref>. Finally,</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Trial participation/placebo effects alleviate symptoms of apathy</head><p><s>Irrespective of the intervention (bupropion or placebo), informants and clinical investigators observed a significant improvement of the symptoms of apathy (AES-I, AES-C) or the apathy syndrome (NPI-Apathy, UHDRS-Apathy) predominantly during the first treatment period Table <ref type="table" target="#tab_5">3</ref>. Notably, this was not observed in the AES-S scores.</s></p><p><s>Study participants also rated their symptoms of apathy as significantly less severe than the caregivers or the clinical investigators Table <ref type="table" target="#tab_2">1</ref>.</s><s>There was also a tendency of a period effect when grading irritability by the UHDRS-Behavior, the SIS or the NPI.</s><s>However, the observations were not consistent between instruments, and the changes in irritability scores were too low to have any clinical relevance (data not shown).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Bupropion does not influence brain structure, brain response or brain connectivity</head><p><s>The analyses of structural and functional MRI data revealed no significant treatment effects.</s><s>We only found a trend toward a decline in the right orbitofrontal cortex gray matter for the bupropion group (ANOVA p = 0.088), and an increase in functional connectivity between the left and right ventral striatum for the bupropion group (ANOVA p = 0.068) S1, S2 and S3 Tables.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>ACTION-HD is the first randomised controlled clinical trial on the treatment of apathy in HD.</s><s>We did not find a clinically significant effect of a 10-week treatment course with bupropion (at a dose of 300 mg per day) on the severity of apathy in HD based on assessments by informant, study participant and clinical investigator using the AES.</s><s>Two further informantbased assessment tools (NPI-Apathy and UHDRS-Apathy) also failed to reveal a treatment effect of bupropion.</s></p><p><s>A concern when designing this trial was the lack of robust longitudinal data on the severity of apathy in HD, since no 'gold standard tool' for the assessment of apathy exists in general <ref type="bibr" target="#b29">[30]</ref>, and for HD in particular.</s><s>We chose the SCIA-D as a screening instrument for the Values are given for the full analysis set as means ± SD (standard deviation) c p = 0.14 after multiple imputation to take missing values into account https://doi.org/10.1371/journal.pone.0173872.t003</s><s>diagnosis of apathy, and the AES as a baseline and follow-up tool to measure the severity of apathy.</s><s>The SCIAD-D is based on the criteria of Starkstein et al. <ref type="bibr" target="#b24">[25]</ref>, which were recently incorporated into the consensus criteria for the diagnosis of apathy proposed by an international task force <ref type="bibr" target="#b30">[31]</ref>.</s><s>The criteria refer to the prior functional status of the study participant, which we judged to be more appropriate than an arbitrarily determined baseline cutoff score.</s><s>The AES is the most widely used rating scale for the symptoms of apathy.</s><s>Clinical studies have also relied on single item measures like the UHDRS-Behavior or the NPI.</s><s>Only recently, the AES has been validated in HD <ref type="bibr" target="#b31">[32]</ref>.</s><s>Importantly, confounding factors like lack of awareness <ref type="bibr" target="#b32">[33]</ref>, comorbid depression, motor symptoms, or side effects of concomitant medication have to be considered when evaluating apathy in HD.</s></p><p><s>The reasons for choosing the AES as the primary rating scale in the ACTION-HD trial included i. the availability of a validated German version <ref type="bibr" target="#b33">[34]</ref>, ii. the possibility of separate ratings by participant, informant and clinician, iii. the good inter-rater reliability for the AES-C <ref type="bibr" target="#b35">[35]</ref>, iv. the separate evaluation of all three domains of apathy <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b25">26]</ref>, v. the provision of performance guidelines by the author, allowing for further standardization <ref type="bibr" target="#b26">[27]</ref>, vi. the suitability of the AES for statistical evaluation due to the 4-point Likert scale, vii. the reasonable length and complexity, allowing for informative answers by cognitively impaired study participants.</s><s>Based on previous reliability studies in AD, the test-retest reliability is 0.94 for the AES-I, 0.88-0.89</s><s>for the AES-C, and 0.76 for the AES-S <ref type="bibr" target="#b26">[27,</ref><ref type="bibr" target="#b36">36]</ref>.</s><s>Power calculations were performed using longitudinal AES data from a recently published HD cohort <ref type="bibr" target="#b31">[32]</ref>.</s><s>AES threshold scores have been suggested for AD with a range from ! 30 to ! 41.5 <ref type="bibr" target="#b37">[37]</ref>, but also for conditions like traumatic brain injury <ref type="bibr" target="#b38">[38]</ref>.</s><s>Baseline scores of some of our patients were below these values Table <ref type="table" target="#tab_2">1</ref>, but there was no doubt about the presence of apathy in these study participants based on the SCIA-D as well as on the clinical assessments.</s><s>Moreover, we found a mean NPI apathy score of 8.6 at baseline in our study.</s><s>NPI apathy scores above 4 have recently been suggested to define clinically significant apathy in dementia <ref type="bibr" target="#b39">[39]</ref>.</s></p><p><s>We chose the informant version of the AES, the AES-I score, as the primary outcome variable since we assumed that HD patients rate their symptoms of apathy less severe than their caregivers or physicians <ref type="bibr" target="#b40">[40,</ref><ref type="bibr" target="#b41">41]</ref>.</s><s>In HD, like in other neuropsychiatric diseases with frontal pathology, lack of insight into symptoms and functional capacities is common <ref type="bibr" target="#b42">[42,</ref><ref type="bibr" target="#b43">43]</ref>.</s><s>Marin originally evaluated the AES in several diseases, including AD <ref type="bibr" target="#b25">[26,</ref><ref type="bibr" target="#b26">27]</ref>, where he observed that patients graded the symptoms of apathy as less severe than their caregivers or clinicians.</s><s>An association with frontal dysfunction has been suggested also for AD <ref type="bibr" target="#b44">[44]</ref>.</s><s>On the other hand, one has to consider that caregivers may be biased by the burden that the patient's apathy bestows on them <ref type="bibr" target="#b45">[45]</ref>.</s><s>As expected, participants of Action-HD rated their symptoms of apathy as significantly less severe than their caregivers or the clinical investigator.</s><s>In addition, a significant period effect was observed for AES-I and AES-C but not for AES-S scores Tables <ref type="table" target="#tab_5">1 and 3</ref>.</s><s>In contrast to these findings, Mason and Barker at the University of Cambridge (UK) did not find a significant difference between AES-I and AES-S sores during an observation period of 19 months on average <ref type="bibr" target="#b31">[32]</ref>.</s><s>An explanation for this discrepancy could be that we physically separated patients and informants when performing the AES, as we previously observed that patients may adapt their judgements to the ratings of the caregivers when assessed in the same setting.</s><s>In addition, the relative number of participants with a TFC score between 7 and 10 was small in the Cambridge study, whereas the mean TFC scores in our study were 7.4 and 8.8 in the intervention groups, respectively.</s><s>Of the 40 patients rated as apathetic by their informants, 21 were lost to follow up in the Cambridge study, which creates a bias.</s><s>Moreover, we excluded patients with dopamine-depleting drugs, and patients with comorbid depression in our study in order to reduce confounding effects.</s><s>This has also recently been recommended by Cummings and coworkers <ref type="bibr" target="#b39">[39]</ref>.</s><s>However, we do acknowledge that HD patients with both depression and apathy may constitute a subgroup that responds better to bupropion than HD patients with apathy alone.</s></p><p><s>To quantify the affective-emotional components of apathy we additionally used an established gambling task to measure reward perception as one of the major preconditions for motivation <ref type="bibr" target="#b23">[24,</ref><ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b46">46]</ref>.</s><s>DA is thought to be involved in reward and motivation, possibly through modification of the mesolimbic and mesocortical pathways, as well as the orbitomedial PFCstriatal projections.</s><s>The loss of DA receptor 1 and 2 expression in fronto-striatal circuits was proposed as a key pathophysiological mechanism of apathy in HD <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b7">8]</ref>.</s><s>Concurrent with the clinical results, we did not detect significant effects of bupropion treatment on brain responses and functional connectivity during reward processing in apathetic HD patients in our exploratory fMRI analysis.</s><s>However, it is difficult to draw any conclusion from the small sample size.</s></p><p><s>When considering the study duration, we feel that 8 weeks on the full dose of bupropion should have been sufficient for the detection of a potential treatment effect.</s><s>The duration of most randomized CTs on apathy in neurodegenerative diseases is between 6 and 12 weeks.</s><s>In fact, Cummings et al. recommended a study duration of 8 to 12 weeks when designing clinical trials for apathy in neurodegenerative diseases since the worsening of apathy in both the verum and placebo arms may result in an underestimation of an initial treatment effect in the intervention arm if the intervention period would be extended beyond 12 weeks <ref type="bibr" target="#b39">[39]</ref>.</s></p><p><s>It is possible that bupropion did not reach sufficient concentrations within the central nervous system at a daily dose of 300mg.</s><s>However, we felt that daily doses of 450 mg could be problematic in advanced stages of HD as the risk of seizures, suicidality and irritability may increase.</s></p><p><s>HD patients in more advanced disease stages often require symptomatic treatment <ref type="bibr" target="#b18">[19]</ref>.</s><s>We cannot exclude the possibility that concomitant medication in some of the study participants may have aggravated apathy or mitigated the effect of bupropion.</s><s>This is particularly true for tiapride, a dopamine D2 and D3 receptor antagonist, which is commonly used to treat chorea in Germany.</s><s>A type 2 error may also result from low sensitivity of the available instruments for grading apathy.</s><s>In the case of the AES, the poor differentiation between the answers 2 ("slightly characteristic") and 3 ("somewhat characteristic") on the four point Likert scale may reduce sensitivity.</s><s>It is noteworthy that the validation of the AES in HD is still incomplete <ref type="bibr" target="#b41">[41]</ref>.</s><s>Our trial adds important data for this process.</s></p><p><s>Many recent drug trials in HD, e.g. the MermaiHD study <ref type="bibr" target="#b47">[47]</ref> and the deutetrabenazine trial <ref type="bibr" target="#b48">[48]</ref>, have detected significant placebo effects.</s><s>Interestingly, Cubo et al. observed a significant placebo effect on behavior, but not on motor symptoms or cognition in a large multicenter drug trial in HD <ref type="bibr" target="#b49">[49]</ref>.</s><s>This effect persisted over 3 years and was prominent if depression was absent.</s><s>In Action-HD, we observed an improvement of the primary outcome measure AES-I for all study participants predominantly prior to crossover.</s><s>This was replicated for the clinician-rated AES-C score.</s><s>Study participants were informed about the crossover design.</s><s>Since we compared period 1 and 2 data with the original baseline, the results suggest, that study participation/placebo effects have a positive impact on the severity of apathy.</s><s>(cf.</s><s>Table <ref type="table" target="#tab_5">3</ref>).</s><s>Notably, the study participants themselves did not rate any improvement on the AES-S.</s><s>These important findings indicate that our study was not underpowered to detect significant changes of apathy using the AES and that, when studying apathy in HD, activation by study participation should be considered when interpreting trial results.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p><s>The ACTION-HD trial suggests that bupropion does not influence the severity of apathy in non-depressed HD patients as quantified by the AES and other behavioral assessment tools.</s></p><p><s>We observed a significant period effect irrespective of the intervention (bupropion or placebo).</s><s>These findings highlight the general need for controlled symptomatic treatment trials in HD.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supporting information</head></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>the influence of bupropion compared to placebo on the change of apathy as quantified by the AES-C (clinician) or the AES-S (self), and the NPI and UHDRS apathy scores, 3. the change of neuropsychiatric symptoms (UHDRS, HADS-SIS), 4. the change of cognitive performance (UHDRS and MMSE), 5. the total motor score (UHDRS), 6. the change of activities of daily living (UHDRS), 7. the change of the NPI caregivers' distress score (NPI-D), and 8. the change of VS and ventromedial PFC activation in response to a gambling task as quantified by fMRI.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig 1 .</head><label>1</label><figDesc><div><p><s>Fig 1. CONSORT flow diagram.</s><s>https://doi.org/10.1371/journal.pone.0173872.g001</s></p></div></figDesc><graphic coords="7,95.98,219.97,479.91,468.17" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>*</head><label></label><figDesc><div><p><s>AES-S vs. AES-I: t (df = 38) = -6.0504,</s><s>p&lt; 0.001, AES-S vs. AES-C: t (df = 38) = -5.6101,</s><s>p-value = &lt;0.001 a N includes all randomized patients b</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head></head><label></label><figDesc><div><p><s>Abbreviations: BMI = Body mass index; UHDRS = Unified Huntington's Disease Rating Scale; TFC = Total Functional Capacity; AES-I = Apathy Evaluation Scale-informant (a friend or family member familiar with the daily activities of the subject); AES-S = AES-self; AES-C = AES-clinician; NPI = Neuropsychiatric Inventory; HADS = Hospital Anxiety and Depression Scale; SIS = Snaith Irritability Scale; SDMT = Symbol Digit Modalities Test; VFT = Verbal Fluency Test; MMSE = Mini Mental State Examination https://doi.org/10.1371/journal.pone.0173872.t001</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head></head><label></label><figDesc><div><p><s>Experimental set up: Slot machine paradigm.</s><s>The period of interest (gain anticipation) is displayed in blue.</s><s>(PDF) S3 Fig. MR-image analysis pipeline.</s><s>Abbreviations: MRI-Magnetic resonance imaging; Sssingle subject; MNI-spatial reference space as defined by the brain template of the Montreal Neurological Institute; ANCOVA-Analysis of covariance, MPRAGE-Magnetization prepared rapid-acquisition gradient-echo image; BOLD-Blood oxygenation dependent; GE-EPI -Gradient-echo echo-planar image, VBM-Voxel-based morphometry, SPM-Statistical parametrical mapping, TPM-Tissue probability map, GA-Gain anticipation, nGA-no Gain anticipation, ROI-Region of Interest, ANCOVA-Analysis of Covariance, VS-Ventral striatum, ACC-Anterior cingulate cortex, MPFC-Medial prefrontal cortex, OFC-Orbitofrontal cortex.</s><s>(PDF) S4 Fig. A-priori computed literature-based, probabilistic Regions Of Interest (ROIs).</s><s>Displayed are tri-orthogonal cuts through the ROI center.</s><s>The outer borders (2SD) of the probabilistic ROIs are displayed in green; the outer borders of the anatomical structures/constraints taken from the AAL-atlas are displayed in red.</s><s>ROI name and the used anatomical constraints are listed left hand, MNI-center coordinates and volume of the ROIs are listed in the right hand part.</s><s>Abbreviations: AAL-Automatically anatomical labeling, MNI-Reference space according to the brain template provided by the Montreal Neurological Institute, Tra-Transversal, Sag-Sagittal, Cor-Coronal, VS-Ventral striatum, ACC-Anterior cingulate cortex, MPFC-Medial prefrontal cortex, OFC-Orbitofrontal cortex, L-Left, R-Right.</s><s>(PDF) S1 Table.</s><s>Treatment associated effects on brain structure (local gray matter volume).</s><s>Interaction between TREATMENT and TIME as revealed by voxel-wise ANCOVA (p &lt; .05</s><s>uncorrected, covariates age &amp; sex).</s><s>Alpha-errors adjusted post-hoc for ROI-volume.</s><s>Post-hoc comparison V(pre&lt;post) &gt; P(pre&lt;post).</s><s>Abbreviations: FEW-Family-wise error, V-Verum, P-Placebo, R-Right, L-Left.</s><s>(DOCX) S2 Table.</s><s>Treatment associated effects on brain response (GA-nGA).</s><s>Interaction between TREATMENT and TIME as revealed by voxel-wise ANCOVA (p &lt; .05</s><s>uncorrected, covariates chorea severity).</s><s>Alpha-errors adjusted post-hoc for ROI-volume.</s><s>Post-hoc comparison V (pre&lt;post) &gt; P(pre&lt;post).</s><s>Abbreviations: FEW-Family-wise error, V-Verum, P-Placebo, R-Right, L-Left.</s><s>(DOCX) S3 Table.</s><s>Treatment associated effects on functional brain connectivity (PPI: GA-nGA).</s><s>Interaction between TREATMENT and TIME as revealed by voxel-wise ANCOVA (p &lt; .05</s><s>uncorrected, covariates chorea severity) for left VS (upper part) and right VS (lower part) separately.</s><s>Alpha-errors adjusted post-hoc for ROI-volume.</s><s>Post-hoc comparison V(pre&lt; post) &gt; P(pre&lt;post).</s><s>Abbreviations: PPI-Psycho-physiological interaction, VS-Ventral striatum, FEW-Family-wise error, V-Verum, P-Placebo, R-Right, L-Left.</s><s>(DOCX)</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head></head><label></label><figDesc><div><p><s>The study was registered and approved by the German Competent Authorities (Bundesinstitut fu ¨r Arzneimittel und Medizinprodukte (registration number 61-3910-4037522; 16.01.2012)</s><s>and the Ethics Commission of the State of Berlin (Ethik-Kommission des Landes Berlin, Landesamt fu ¨r Gesundheit und Soziales; registration number 11/0351-ZS EK; 27.01.2012),</s><s>Berlin, Germany, as well as the institutional review boards of the Universities of Bochum, Mu ¨nster and Ulm (Clinical Trial protocol version 1.1.</s><s>[17.11.2012], version 2.0 [amendment 2; 22.02.13];</s><s>patient informed consent form version 2.0 [17.11.2011], version 3.0 [amendment 2; 22.02.13];</s><s>informant informed consent form version 1.0</s></p></div></figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head></head><label></label><figDesc><div><p><s>research grant support from the CHDI Foundation, the Bundesministerium fu ¨r Bildung und Forschung (BMBF), the Deutsche Forschungsgemeinschaft (DFG), the European Commission (EU-FP7).</s><s>His study site Ulm has received compensation in the context of the observational REGISTRY-Study of EHDN.</s><s>Josef Priller is an academic editor of PLOS ONE.</s><s>He has no competing interests in relation to the submitted trial.</s><s>He has advisory function for Neurimmune, has a licensed patent with Epomedics, gave paid lectures for Desitin Arzneimittel GmbH and has provided trial services for EHDN, Teva, Pfizer, TauRx, DZNE (Deutsches Zentrum fu ¨r Neurodegenerative Erkrankungen), CHDI, Axovant.</s><s>He is a member of DGPPN (Deutsche Gesellschaft fu ¨r Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde), DGBP (Deutsche Gesellschaft fu ¨r Biologische Psychiatrie), IGSLI (International Group for The Study of Lithium Treated Patients), DZNE and EHDN.</s><s>This does not alter our adherence to PLOS ONE policies on sharing data and materials.</s></p></div></figDesc><table><row><cell>Abbreviations: AD, Alzheimer's disease; AE,</cell></row><row><cell>adverse event; AES-C, Apathy Evaluation Scale-</cell></row><row><cell>Clinician; AES-I, Apathy Evaluation Scale-</cell></row><row><cell>Informant; AES-S, Apathy Evaluation Scale-Self;</cell></row><row><cell>BG, basal ganglia; C-SSRS, Columbia-Suicide</cell></row><row><cell>Severity Rating Scale; CT, controlled trial; DA,</cell></row><row><cell>dopamine; fMRI, functional magnetic resonance</cell></row><row><cell>imaging; HADS-SIS, The Hospital Anxiety and</cell></row><row><cell>Depression Scale combined with the Snaith</cell></row><row><cell>Irritability Scale; HD, Huntington's disease; IIT,</cell></row><row><cell>investigator initiated trial; MMSE, Mini Mental</cell></row><row><cell>Status Examination; NPI, Neuropsychiatric</cell></row><row><cell>Inventory; NPI-D, NPI-distress; PFC, prefrontal</cell></row><row><cell>cortex; ROIs, regions of interest; SCIA-D,</cell></row><row><cell>Structured Clinical Interview for Apathy-</cell></row><row><cell>Dementia; UHDRS, Unified Huntington's Disease</cell></row><row><cell>Rating Scale; VS, ventral striatum.</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 1 . Demographic data and neuropsychiatric profiles (full analysis set). Group 1 (bupropion/placebo) b Group 2 (placebo/bupropion) b</head><label>1</label><figDesc></figDesc><table><row><cell>Number of participants a</cell><cell>20</cell><cell>20</cell><cell></cell></row><row><cell>Age, years (mean ± SD) c</cell><cell>54.6 ± 8.5</cell><cell>54.3 ± 10.7</cell><cell></cell></row><row><cell>Males (number)</cell><cell>11</cell><cell>15</cell><cell></cell></row><row><cell>Weight, kg (mean ± SD)</cell><cell>78.4 ± 14.4</cell><cell>80.7 ± 18.7</cell><cell></cell></row><row><cell>BMI (mean ± SD)</cell><cell>25.1 ± 3.2</cell><cell>26.5 ± 5.2</cell><cell></cell></row><row><cell>CAG repeats (mean ± SD)</cell><cell>43.6 ± 2.3</cell><cell>43.9 ± 3.7</cell><cell></cell></row><row><cell>Duration of disease (years)</cell><cell>8.4 ± 3.6</cell><cell>5.5 ± 2.4 d</cell><cell>p&lt;0.05</cell></row><row><cell>Concomitant medication with tiapride</cell><cell>11</cell><cell>11</cell><cell></cell></row><row><cell>UHDRS-Motor (mean ± SD)</cell><cell>39.3 ± 12.3</cell><cell>34.1 ± 12.6 e</cell><cell></cell></row><row><cell>TFC (mean ± SD)</cell><cell>7.40 ± 2.7</cell><cell>8.8 ± 3.5</cell><cell></cell></row><row><cell>Apathy</cell><cell></cell><cell></cell><cell></cell></row><row><cell>AES-I (mean ± SD)</cell><cell>36.4 ± 7.9</cell><cell>34.2 ± 7.7</cell><cell></cell></row><row><cell>AES-S (mean ± SD)</cell><cell>29.3 ± 4</cell><cell>22.7 ± 8.6 e, *</cell><cell></cell></row><row><cell>AES-C (mean ± SD)</cell><cell>36.0 ± 6.9</cell><cell>32.6 ± 7.9 e, *</cell><cell></cell></row><row><cell>NPI-Apathy (mean ± SD)</cell><cell>8.8 ± 2.1</cell><cell>8.7 ± 2.1</cell><cell></cell></row><row><cell>UHDRS-Apathy (mean ± SD)</cell><cell>10 ± 2</cell><cell>9.4 ± 3</cell><cell></cell></row><row><cell>Depression/irritability</cell><cell></cell><cell></cell><cell></cell></row><row><cell>NPI-Depression (mean ± SD)</cell><cell>0.7 ± 1.1</cell><cell>0.8 ± 1</cell><cell></cell></row><row><cell>HADS-Depression (mean ± SD)</cell><cell>9.7 ± 4.6 e</cell><cell>8.2 ± 4.1</cell><cell></cell></row><row><cell>NPI-Irritability (mean ± SD)</cell><cell>1.5 ± 1.9</cell><cell>2.2 ± 2.1</cell><cell></cell></row><row><cell>SIS (mean ± SD)</cell><cell>5.1 ± 3.1 e</cell><cell>6.1 ± 4.1</cell><cell></cell></row><row><cell>Cognition</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Stroop interference (mean ± SD)</cell><cell>22.1 ± 9</cell><cell>20.5 ± 10.6</cell><cell></cell></row><row><cell>SDMT (mean ± SD)</cell><cell>19.5 ± 8.6</cell><cell>22.1 ± 12</cell><cell></cell></row><row><cell>VFT (mean ± SD)</cell><cell>17.3 ± 12.2</cell><cell>22.3 ± 14.0</cell><cell></cell></row><row><cell>MMSE (mean ± SD)</cell><cell>26.9 ± 2.</cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 2 . No change of apathy, irritability, cognition or function after 10 weeks of treatment with bupropion. Full analysis set Per protocol set Treatment effect [CI] p-value Treatment effect [CI] p-value Apathy AES-I a -0.81 [-3.1, 1.5] 0.5 -0.09 [-2.6, 2.4] 0.9</head><label>2</label><figDesc></figDesc><table><row><cell>AES-S</cell><cell>-2.15 [-4.6, 0.3]</cell><cell>0.1</cell><cell>-2.23 [-4.9, 0.4]</cell><cell>0.1</cell></row><row><cell>AES-C</cell><cell>-1.64 [-3.9, 0.7]</cell><cell>0.2</cell><cell>-1.26 [-3.7, 1.2]</cell><cell>0.3</cell></row><row><cell>NPI-Apathy</cell><cell>-0.79 [-1.8, 0.2]</cell><cell>0.1</cell><cell>-0.53 [-1.6, 0.5]</cell><cell>0.3</cell></row><row><cell>UHDRS-Apathy</cell><cell>-0.88 [-2.2, 0.4]</cell><cell>0.2</cell><cell>-0.71 [-2, 0.6]</cell><cell>0.3</cell></row><row><cell>Depression/irritability</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>NPI-Depression</cell><cell>-0.62 [-1.3, 0.04]</cell><cell>0.07</cell><cell>-0.65 [-1.4, 0.1]</cell><cell>0.1</cell></row><row><cell>HADS-Depression</cell><cell>0.09 [-1.3, 1.5]</cell><cell>0.9</cell><cell>-0.16 [-1.7, 1.4]</cell><cell>0.8</cell></row><row><cell>NPI-Irritability</cell><cell>0.01 [-0.7, 0.8]</cell><cell>1</cell><cell>0.00 [-0.8, 0.8]</cell><cell>1.0</cell></row><row><cell>SIS (irritability)</cell><cell>-0.07 [-1.1, 1]</cell><cell>0.9</cell><cell>-0.20 [-1.3, 0.9]</cell><cell>0.7</cell></row><row><cell>Cognition</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Stroop (interference)</cell><cell>-0.03 [-1.9, 1.7]</cell><cell>1</cell><cell>0.38 [-1.3, 2]</cell><cell>0.6</cell></row><row><cell>SDMT</cell><cell>1.30 [-0.1, 2.7]</cell><cell>0.1</cell><cell>1.26 [-0.1, 2.6]</cell><cell>0.1</cell></row><row><cell>VFT</cell><cell>-0.16 [-2.1, 1.8]</cell><cell>0.9</cell><cell>-0.41 [-2.4, 1.6]</cell><cell>0.7</cell></row><row><cell>MMSE</cell><cell>0.59 [-0.2, 1.4]</cell><cell>0.1</cell><cell>0.77 [-0.1, 1.6]</cell><cell>0.1</cell></row><row><cell>Distress caregiver</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>NPI-D (apathy)</cell><cell>0.14 [-0.3, 0.6]</cell><cell>0.5</cell><cell>0.21 [-0.2, 0.7]</cell><cell>0.3</cell></row><row><cell>Functional scores</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>UHDRS-Motor</cell><cell>-0.64 [-2.7, 1.5]</cell><cell>0.5</cell><cell>-0.45 [-2.7, 1.8]</cell><cell>0.7</cell></row><row><cell>TFC</cell><cell>0.33 [-0.1, 0.7]</cell><cell>0.1</cell><cell>0.38 [0, 0.8]</cell><cell>0.07</cell></row><row><cell>UHDRS-Function</cell><cell>0.29 [-0.3, 0.9]</cell><cell>0.3</cell><cell>0.29 [-0.3, 0.9]</cell><cell>0.4</cell></row><row><cell>UHDRS-Independence</cell><cell>-0.53 [-2.2, 1.1]</cell><cell>0.5</cell><cell>-0.59 [-2.3, 1.2]</cell><cell>0.5</cell></row></table><note><p><s>a Results are given as treatment effect and 95% confidence interval.</s><s>The primary outcome parameter is shown in bold.</s><s>Inferential statistical evaluation of the primary and secondary outcome parameters were based on a linear mixed effects model with the AES-I score as dependent variable using only the first baseline before treatment.</s><s>The significance level was set to 0.05.</s><s>https://doi.org/10.1371/journal.pone.0173872.t002</s><s>caregiver distress was not alleviated by treatment of apathetic HD patients with bupropion</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Taken together, there was no change of any clinical secondary outcome parameter as a result of bupropion treatment.</s></p></div></figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 3 . Change of apathy after the first treatment period suggests activation through trial participation. Instrument Score (min/max) a Baseline b Period 1 b Period 2 b p-value</head><label>3</label><figDesc></figDesc><table><row><cell>AES-I</cell><cell>0-54</cell><cell>35.3 ± 7.8</cell><cell>32.6 ± 9.5</cell><cell>31.1 ± 10.3</cell><cell>&lt; 0.005 c</cell></row><row><cell>AES-S</cell><cell>0-54</cell><cell>26.1 ± 8.6</cell><cell>26.5 ± 8.3</cell><cell>26.3 ± 9.5</cell><cell>0.9</cell></row><row><cell>AES-C</cell><cell>0-54</cell><cell>34.4 ± 7.5</cell><cell>32 ± 8.4</cell><cell>31 ± 9.3</cell><cell>&lt; 0.05</cell></row><row><cell>NPI-Apathy</cell><cell>1-12</cell><cell>8.6 ± 2.5</cell><cell>7 ± 3</cell><cell>6.7 ± 3.3</cell><cell>&lt; 0.001</cell></row><row><cell>UHDRS-Apathy</cell><cell>0-16</cell><cell>9.7 ± 2.5</cell><cell>8.7 ± 3.17</cell><cell>7.9 ± 3.9</cell><cell>&lt; 0.05</cell></row><row><cell>NPI-D Apathy</cell><cell>0-5</cell><cell>3.35 ± 1</cell><cell>3.1 ± 1.1</cell><cell>2.7 ± 1.2</cell><cell>&lt; 0.01</cell></row><row><cell cols="6">a Minimum and maximum values of the instruments used to grade apathetic symptoms (AES), apathy as syndrome (NPI, UHDRS) or caregiver distress due</cell></row><row><cell>to apathy (NPI-D)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>b</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">PLOS ONE | https://doi.org/10.1371/journal.pone.0173872 March 21, 2017 2 / 17</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">PLOS ONE | https://doi.org/10.1371/journal.pone.0173872March 21, 2017  </note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>The authors thank Sarah L. Mason and Roger A. Barker (Centre for Brain Repair, University of Cambridge, UK) for providing preliminary AES data for the power analysis.</s><s>We also thank David Craufurd (University of Manchester, UK) for sharing his experience with assessments in HD.</s><s>We are indebted to Katrin Barth, Carolin Geitner, Sonja Trautmann, Barabara Kaminski, Christiane Stamm and Ralf Reilmann from the Huntington Centres in Ulm, Bochum and Mu ¨nster for their assistance with the trial.</s><s>We thank Andrea Hassenpflug, Yvonne Kamm and Stefan Hetzer (BCAN, Berlin) for their expert assistance with neuroimaging.</s><s>Last but not least, we thank the many participants and caregivers who generously agreed to participate in this trial.</s><s>The authors also thank those at HSC/HSG and EHDN, who did not lose confidence in the finalization of this first IIT on the symptomatic treatment of neuropsychiatric symptoms in HD.</s></p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Behavioral changes in Huntington Disease</title>
		<author>
			<persName><forename type="first">D</forename><surname>Craufurd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Snowden</surname></persName>
		</author>
		<idno type="PMID">11725215</idno>
	</analytic>
	<monogr>
		<title level="j">Neuropsychiatry, neuropsychology, and behavioral neurology</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="219" to="226" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits</title>
		<author>
			<persName><forename type="first">R</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dubois</surname></persName>
		</author>
		<idno type="DOI">10.1093/cercor/bhj043</idno>
		<idno type="PMID">16207933</idno>
		<ptr target="https://doi.org/10.1093/cercor/bhj043" />
	</analytic>
	<monogr>
		<title level="j">Cerebral cortex</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="916" to="928" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">The nosological position of apathy in clinical practice</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Starkstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Leentjens</surname></persName>
		</author>
		<idno type="DOI">10.1136/jnnp.2007.136895</idno>
		<idno type="PMID">18187477</idno>
		<ptr target="https://doi.org/10.1136/jnnp.2007.136895" />
	</analytic>
	<monogr>
		<title level="j">Journal of neurology</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1088" to="1092" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington&apos;s disease in the TRACK-HD study: analysis of 36-month observational data</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Tabrizi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">I</forename><surname>Scahill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Owen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Durr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Leavitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Roos</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1474-4422(13)70088-7</idno>
		<idno type="PMID">23664844</idno>
		<ptr target="https://doi.org/10.1016/S1474-4422" />
	</analytic>
	<monogr>
		<title level="j">The Lancet Neurology</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="70088" to="70095" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<monogr>
		<title level="m" type="main">Neuropsychiatric symptoms in a European Huntington&apos;s disease cohort (REGISTRY)</title>
		<author>
			<persName><forename type="first">E</forename><surname>Van Duijn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Craufurd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Hubers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Giltay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bonelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Rickards</surname></persName>
		</author>
		<idno type="DOI">10.1136/jnnp-2013-307343</idno>
		<idno type="PMID">24828898</idno>
		<ptr target="https://doi.org/10.1136/jnnp-2013-307343" />
		<imprint>
			<date type="published" when="2014">2014</date>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="page" from="1411" to="1418" />
		</imprint>
	</monogr>
	<note>Journal of neurology, neurosurgery, and psychiatry</note>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title level="m" type="main">Cognitive impairment related to apathy in early Huntington&apos;s disease. Dementia and geriatric cognitive disorders</title>
		<author>
			<persName><forename type="first">S</forename><surname>Baudic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Maison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dolbeau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Boisse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bartolomeo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dalla</forename><surname>Barba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
		<idno type="DOI">10.1159/000091523</idno>
		<idno type="PMID">16484810</idno>
		<ptr target="https://doi.org/10.1159/000091523" />
		<imprint>
			<date type="published" when="2006">2006</date>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="316" to="321" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title level="m" type="main">Dopamine and Huntington&apos;s disease. Expert review of neurotherapeutics</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Schwab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">N</forename><surname>Garas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Drouin-Ouellet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Mason</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Stott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Barker</surname></persName>
		</author>
		<imprint>
			<biblScope unit="volume">2015</biblScope>
			<biblScope unit="page" from="1" to="14" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Dopamine and glutamate in Huntington&apos;s disease: A balancing act</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">M</forename><surname>Andre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cepeda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Levine</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">CNS neuroscience &amp; therapeutics</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="163" to="178" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Huntington&apos;s Disease and Striatal Signaling</title>
		<author>
			<persName><forename type="first">Roze</forename><forename type="middle">E</forename><surname>Cahill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bonnet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Vanhoutte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Betuing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
		<idno type="DOI">10.3389/fnana.2011.00055</idno>
		<idno type="PMID">22007160</idno>
		<ptr target="https://doi.org/10.3389/fnana.2011.00055" />
	</analytic>
	<monogr>
		<title level="j">Frontiers in neuroanatomy</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">55</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<title level="m" type="main">Consistent neurodegeneration and its association with clinical progression in Huntington&apos;s disease: a coordinate-based meta-analysis. Neuro-degenerative diseases</title>
		<author>
			<persName><forename type="first">I</forename><surname>Dogan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Eickhoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Schulz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Laird</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">T</forename><surname>Fox</surname></persName>
		</author>
		<idno type="DOI">10.1159/000339528</idno>
		<idno type="PMID">22922585</idno>
		<ptr target="https://doi.org/10.1159/000339528" />
		<imprint>
			<date type="published" when="2013">2013</date>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="23" to="35" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<title level="m" type="main">Longitudinal evaluation of neuropsychiatric symptoms in Huntington&apos;s disease. The Journal of neuropsychiatry and clinical neurosciences</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Sollom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Stopford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Howard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Snowden</surname></persName>
		</author>
		<idno type="DOI">10.1176/appi.neuropsych.11030057</idno>
		<idno type="PMID">22450614</idno>
		<ptr target="https://doi.org/10.1176/appi.neuropsych.11030057" />
		<imprint>
			<date type="published" when="2012">2012</date>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="53" to="60" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Distribution of grey matter atrophy in Huntington&apos;s disease patients: a combined ROI-based and voxel-based morphometric study</title>
		<author>
			<persName><forename type="first">G</forename><surname>Douaud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Gaura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Ribeiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lethimonnier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Maroy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Verny</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.neuroimage.2006.05.057</idno>
		<idno type="PMID">16875847</idno>
		<ptr target="https://doi.org/10.1016/j.neuroimage.2006.05.057" />
	</analytic>
	<monogr>
		<title level="j">NeuroImage</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1562" to="1575" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease</title>
		<author>
			<persName><forename type="first">C</forename><surname>Fennema-Notestine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Archibald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Jacobson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Corey-Bloom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Paulsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Peavy</surname></persName>
		</author>
		<idno type="PMID">15452288</idno>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="989" to="995" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Topography of cerebral atrophy in early Huntington&apos;s disease: a voxel based morphometric MRI study</title>
		<author>
			<persName><forename type="first">J</forename><surname>Kassubek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">D</forename><surname>Juengling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kioschies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Henkel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Karitzky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kramer</surname></persName>
		</author>
		<idno type="PMID">14742591</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of neurology</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="213" to="220" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Mesolimbic functional magnetic resonance imaging activations during reward anticipation correlate with reward-related ventral striatal dopamine release</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">H</forename><surname>Schott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Minuzzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Krebs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Elmenhorst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">H</forename><surname>Winz</surname></persName>
		</author>
		<idno type="DOI">10.1523/JNEUROSCI.2058-08.2008</idno>
		<idno type="PMID">19109512</idno>
		<ptr target="https://doi.org/10.1523/JNEUROSCI.2058-08" />
	</analytic>
	<monogr>
		<title level="j">J Neurosci</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">52</biblScope>
			<biblScope unit="page" from="14311" to="14319" />
			<date type="published" when="2008">2008. 2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">FMRI visualization of brain activity during a monetary incentive delay task</title>
		<author>
			<persName><forename type="first">B</forename><surname>Knutson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Westdorp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kaiser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hommer</surname></persName>
		</author>
		<idno type="DOI">10.1006/nimg.2000.0593</idno>
		<idno type="PMID">10875899</idno>
		<ptr target="https://doi.org/10.1006/nimg.2000.0593" />
	</analytic>
	<monogr>
		<title level="j">NeuroImage</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="20" to="27" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Altered ventral striatal activation during reward and punishment processing in premanifest Huntington&apos;s disease: a functional magnetic resonance study</title>
		<author>
			<persName><forename type="first">B</forename><surname>Enzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Edel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lissek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Peters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hoffmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Nicolas</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.expneurol.2012.02.003</idno>
		<idno type="PMID">22366326</idno>
		<ptr target="https://doi.org/10.1016/j.expneurol.2012.02.003" />
	</analytic>
	<monogr>
		<title level="j">Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">235</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="256" to="264" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Treatment of Apathy in Huntington&apos;s Disease and Other Movement Disorders</title>
		<author>
			<persName><forename type="first">A</forename><surname>Krishnamoorthy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Craufurd</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11940-011-0140-y</idno>
		<idno type="PMID">21800056</idno>
		<ptr target="https://doi.org/10.1007/s11940-011-0140-y" />
	</analytic>
	<monogr>
		<title level="j">Current treatment options in neurology</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="508" to="519" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Advancing pharmacotherapy for treating Huntington&apos;s disease: a review of the existing literature</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Mason</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Barker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Opin Pharmacother</title>
		<imprint>
			<biblScope unit="volume">2015</biblScope>
			<biblScope unit="page" from="1" to="12" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<monogr>
		<title level="m" type="main">Apathy: a treatable syndrome. The Journal of neuropsychiatry and clinical neurosciences</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Marin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Fogel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hawkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Duffy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Krupp</surname></persName>
		</author>
		<idno type="DOI">10.1176/jnp.7.1.23</idno>
		<idno type="PMID">7711487</idno>
		<ptr target="https://doi.org/10.1176/jnp.7.1.23" />
		<imprint>
			<date type="published" when="1995">1995</date>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="23" to="30" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Bupropion in the management of apathy</title>
		<author>
			<persName><forename type="first">C</forename><surname>Corcoran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>'keane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename></persName>
		</author>
		<idno type="DOI">10.1177/0269881104043284</idno>
		<idno type="PMID">15107198</idno>
		<ptr target="https://doi.org/10.1177/0269881104043284" />
	</analytic>
	<monogr>
		<title level="j">J Psychopharmacol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="133" to="135" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Bupropion: first experience in Huntington&apos;s Disease</title>
		<author>
			<persName><forename type="first">K</forename><surname>Strassburger</surname></persName>
		</author>
		<author>
			<persName><surname>Aj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Saft</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurosurg Psychiatry</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="page" from="A29" to="30" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>J Neurol</note>
</biblStruct>

<biblStruct xml:id="b22">
	<monogr>
		<title level="m" type="main">Apathy is associated with volume of the nucleus accumbens in patients infected with HIV. The Journal of neuropsychiatry and clinical neurosciences</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Paul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Brickman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Navia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hinkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">F</forename><surname>Malloy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Jefferson</surname></persName>
		</author>
		<idno type="DOI">10.1176/appi.neuropsych.17.2.167</idno>
		<idno type="PMID">15939969</idno>
		<ptr target="https://doi.org/10.1176/appi.neuropsych.17.2.167" />
		<imprint>
			<date type="published" when="2005">2005</date>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="167" to="171" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Reward anticipation in the adolescent and aging brain</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Lorenz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Gleich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Beck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Pohland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Raufelder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sommer</surname></persName>
		</author>
		<idno type="DOI">10.1002/hbm.22540</idno>
		<idno type="PMID">24801222</idno>
		<ptr target="https://doi.org/10.1002/hbm.22540" />
	</analytic>
	<monogr>
		<title level="j">Hum Brain Mapp</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="5153" to="5165" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">On the overlap between apathy and depression in dementia</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Starkstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ingram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Garau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mizrahi</surname></persName>
		</author>
		<idno type="DOI">10.1136/jnnp.2004.052795</idno>
		<idno type="PMID">16024880</idno>
		<ptr target="https://doi.org/10.1136/jnnp.2004.052795" />
	</analytic>
	<monogr>
		<title level="j">Journal of neurology</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1070" to="1074" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<monogr>
		<title level="m" type="main">Apathy: a neuropsychiatric syndrome. The Journal of neuropsychiatry and clinical neurosciences</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Marin</surname></persName>
		</author>
		<idno type="DOI">10.1176/jnp.3.3.243</idno>
		<idno type="PMID">1821241</idno>
		<ptr target="https://doi.org/10.1176/jnp.3.3.243" />
		<imprint>
			<date type="published" when="1991">1991</date>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="243" to="254" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Reliability and validity of the Apathy Evaluation Scale</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Marin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Biedrzycki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Firinciogullari</surname></persName>
		</author>
		<idno type="PMID">1754629</idno>
	</analytic>
	<monogr>
		<title level="j">Psychiatry Res</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="143" to="162" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<monogr>
		<title level="m" type="main">Unified Huntington&apos;s Disease Rating Scale: reliability and consistency. Huntington Study Group. Movement disorders: official journal of the Movement</title>
		<imprint>
			<date type="published" when="1996">1996</date>
			<publisher>Disorder Society</publisher>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="136" to="142" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Age differences in neural activity during slot machine gambling: an fMRI study</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Mccarrey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Henry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Von Hippel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Weidemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Sachdev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Wohl</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0049787</idno>
		<idno type="PMID">23209599</idno>
		<ptr target="https://doi.org/10.1371/journal.pone.0049787" />
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page">e49787</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Quantifying motivational deficits and apathy: a review of the literature</title>
		<author>
			<persName><forename type="first">M</forename><surname>Weiser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Garibaldi</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.euroneuro.2014.08.018</idno>
		<idno type="PMID">25863434</idno>
		<ptr target="https://doi.org/10.1016/j.euroneuro.2014.08.018" />
	</analytic>
	<monogr>
		<title level="j">Eur Neuropsychopharmacol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1060" to="1081" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Proposed diagnostic criteria for apathy in Alzheimer&apos;s disease and other neuropsychiatric disorders. European psychiatry: the journal of the Association of</title>
		<author>
			<persName><forename type="first">P</forename><surname>Robert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">U</forename><surname>Onyike</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Leentjens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dujardin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Aalten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Starkstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">European Psychiatrists</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="98" to="104" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<monogr>
		<title level="m" type="main">Rating Apathy in Huntington&apos;s Disease: Patients and Companions Agree</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mason</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Barker</surname></persName>
		</author>
		<idno type="PMID">26333257</idno>
		<imprint>
			<date type="published" when="2015">2015</date>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="49" to="59" />
		</imprint>
	</monogr>
	<note>Journal of Huntington&apos;s disease</note>
</biblStruct>

<biblStruct xml:id="b32">
	<monogr>
		<title level="m" type="main">Frontal&quot; behaviors before the diagnosis of Huntington&apos;s disease and their relationship to markers of disease progression: evidence of early lack of awareness. The Journal of neuropsychiatry and clinical neurosciences</title>
		<author>
			<persName><forename type="first">K</forename><surname>Duff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Paulsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Beglinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Langbehn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Stout</surname></persName>
		</author>
		<idno type="DOI">10.1176/appi.neuropsych.22.2.196</idno>
		<idno type="PMID">20463114</idno>
		<ptr target="https://doi.org/10.1176/appi.neuropsych.22.2.196" />
		<imprint>
			<date type="published" when="2010">2010</date>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="196" to="207" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">U</forename><surname>Lueken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Seidl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schwarz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Volker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Naumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mattes</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>Psychometric properties of a German version of the Apathy Evaluation Scale</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title/>
		<idno type="DOI">10.1055/s-2006-932164</idno>
		<idno type="PMID">17167730</idno>
		<ptr target="https://doi.org/10.1055/s-2006-932164" />
	</analytic>
	<monogr>
		<title level="j">Fortschritte der Neurologie-Psychiatrie</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="714" to="722" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Are the available apathy measures reliable and valid? A review of the psychometric evidence</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Clarke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Ko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Kuhl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Van Reekum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Salvador</forename><forename type="middle">R</forename><surname>Marin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.jpsychores.2010.01.012</idno>
		<idno type="PMID">21193104</idno>
		<ptr target="https://doi.org/10.1016/j.jpsychores.2010.01.012" />
	</analytic>
	<monogr>
		<title level="j">Journal of psychosomatic research</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="73" to="97" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Validation of apathy evaluation scale and assessment of severity of apathy in Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Hsieh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Chu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Lin</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1440-1819.2011.02315.x</idno>
		<idno type="PMID">22443245</idno>
		<ptr target="https://doi.org/10.1111/j.1440-1819.2011.02315.x" />
	</analytic>
	<monogr>
		<title level="j">Psychiatry Clin Neurosci</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="227" to="234" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Diagnostic criteria for apathy in clinical practice</title>
		<author>
			<persName><forename type="first">E</forename><surname>Mulin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Leone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dujardin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Delliaux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Leentjens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Nobili</surname></persName>
		</author>
		<idno type="DOI">10.1002/gps.2508</idno>
		<idno type="PMID">20690145</idno>
		<ptr target="https://doi.org/10.1002/gps.2508" />
	</analytic>
	<monogr>
		<title level="j">International journal of geriatric psychiatry</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="158" to="165" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Measuring apathy after traumatic brain injury: Psychometric properties of the Apathy Evaluation Scale and the Frontal Systems Behavior Scale</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Lane-Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Tate</surname></persName>
		</author>
		<idno type="DOI">10.3109/02699050903379347</idno>
		<idno type="PMID">19891539</idno>
		<ptr target="https://doi.org/10.3109/02699050903379347" />
	</analytic>
	<monogr>
		<title level="j">Brain injury</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">13-14</biblScope>
			<biblScope unit="page" from="999" to="1007" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Apathy in Neurodegenerative Diseases: Recommendations on the Design of</title>
		<author>
			<persName><forename type="first">J</forename><surname>Cummings</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Friedman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Garibaldi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Macfadden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Marsh</surname></persName>
		</author>
		<idno type="DOI">10.1177/0891988715573534</idno>
		<idno type="PMID">25809634</idno>
		<ptr target="https://doi.org/10.1177/0891988715573534" />
	</analytic>
	<monogr>
		<title level="j">Clinical Trials. Journal of geriatric psychiatry and neurology</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="159" to="173" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<monogr>
		<title level="m" type="main">A comparison of self-report and caregiver assessment of depression, apathy, and irritability in Huntington&apos;s disease. The Journal of neuropsychiatry and clinical neurosciences</title>
		<author>
			<persName><forename type="first">A</forename><surname>Chatterjee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename><surname>Moskowitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Hauser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Marder</surname></persName>
		</author>
		<idno type="DOI">10.1176/jnp.17.3.378</idno>
		<idno type="PMID">16179661</idno>
		<ptr target="https://doi.org/10.1176/jnp.17.3.378" />
		<imprint>
			<date type="published" when="2005">2005</date>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="378" to="383" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Rating scales for behavioral symptoms in Huntington&apos;s disease: Critique and recommendations</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Mestre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Van Duijn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Bachoud-Levi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Busse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Anderson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Movement disorders: official journal of the Movement Disorder Society</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1466" to="1478" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<monogr>
		<title level="m" type="main">Huntington&apos;s disease patients have selective problems with insight. Movement disorders: official journal of the</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Ho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">O</forename><surname>Robbins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Barker</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2006">2006</date>
			<publisher>Movement Disorder Society</publisher>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="385" to="389" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<monogr>
		<title level="m" type="main">Patients with Huntington&apos;s disease have impaired awareness of cognitive, emotional, and functional abilities</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">F</forename><surname>Hoth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Paulsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Moser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Tranel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Clark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bechara</surname></persName>
		</author>
		<idno type="DOI">10.1080/13803390600718958</idno>
		<idno type="PMID">17497560</idno>
		<ptr target="https://doi.org/10.1080/13803390600718958" />
		<imprint>
			<date type="published" when="2007">2007</date>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="365" to="376" />
		</imprint>
	</monogr>
	<note>Journal of clinical and experimental neuropsychology</note>
</biblStruct>

<biblStruct xml:id="b44">
	<monogr>
		<title level="m" type="main">Anosognosia in Alzheimer&apos;s disease: diagnosis, frequency, mechanism and clinical correlates. Cortex; a journal devoted to the study of the nervous system and behavior</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Starkstein</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cortex.2014.07.019</idno>
		<idno type="PMID">25481465</idno>
		<ptr target="https://doi.org/10.1016/j.cortex.2014.07.019" />
		<imprint>
			<date type="published" when="2014">2014</date>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="64" to="73" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Caregiver rating bias in mild cognitive impairment and mild Alzheimer&apos;s disease: impact of caregiver burden and depression on dyadic rating discrepancy across domains</title>
		<author>
			<persName><forename type="first">L</forename><surname>Pfeifer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Drobetz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fankhauser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Mortby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Maercker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Forstmeier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">International psychogeriatrics / IPA</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1345" to="1355" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Characterization of reward and effort mechanisms in apathy</title>
		<author>
			<persName><forename type="first">V</forename><surname>Bonnelle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Veromann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Burnett Heyes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lo</forename><surname>Sterzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Manohar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Husain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of physiology</title>
		<imprint>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Pridopidine for the treatment of motor function in patients with Huntington&apos;s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>De Yebenes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Landwehrmeyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Squitieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Reilmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rosser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Barker</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1474-4422(11)70233-2</idno>
		<idno type="PMID">22071279</idno>
		<ptr target="https://doi.org/10.1016/S1474-4422(11)70233-2" />
	</analytic>
	<monogr>
		<title level="j">The Lancet Neurology</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1049" to="1057" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial</title>
		<author>
			<persName><forename type="first">Huntington</forename><surname>Study</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Frank</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Testa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Stamler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kayson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
		<idno type="DOI">10.1001/jama.2016.8655</idno>
		<idno type="PMID">27380342</idno>
		<ptr target="https://doi.org/10.1001/jama.2016.8655" />
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">316</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="40" to="50" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<monogr>
		<title level="m" type="main">Placebo effect characteristics observed in a single, international, longitudinal study in Huntington&apos;s disease. Movement disorders: official journal of the</title>
		<author>
			<persName><forename type="first">E</forename><surname>Cubo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gonzalez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Del Puerto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>De Yebenes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">F</forename><surname>Arconada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Gabriel Y Galan</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2012">2012</date>
			<publisher>Movement Disorder Society</publisher>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="439" to="442" />
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
